No Data
No Data
China Post Securities: ADC drug innovation drives development, and the industry's high prosperity continues.
Several varieties with sales amounts reaching tens of billions of yuan are expected to emerge in the domestic ADC drug field, with many biopharmaceutical and biotechnology companies focused on layout. It is recommended to actively pay attention to pharmaceutical companies with smooth clinical progress and overseas prospects.
Baolitianheng (688506.SH): Zhu Yi accumulated shareholding of 0.05 million shares.
On July 23, Gelunhui reported that as of July 22, 2024, Mr. Zhu Yi acquired a total of 50,520 shares of the company through the Shanghai Stock Exchange trading system in a centralized bidding trading method, accounting for 0.01% of the company's total share capital. The total shareholding amount was RMB 8.2821 million (excluding stamp duty, transaction commission and other transaction costs), and the shareholding plan implementation was completed.
Bailitianheng (688506.SH): Injection use of BL-M14D1 (ADC) project for the treatment of advanced solid tumors has obtained the Phase I clinical trial approval notice.
On July 11th, Gelunhui reported that Baili Tianheng (688506.SH) recently received the "Drug Clinical Trial Approval Notice" officially issued by the National Medical Products Administration (NMPA). The clinical trial of the company's independently developed innovative biological drug BL-M14D1 (ADC) has been approved. BL-M14D1 is an ADC drug that shares the same "linker + toxin" platform as BL-B01D1, both of which are derived from the same small molecule technology platform. Its indication is late-stage solid tumors.
Sichuan Biokin Pharmaceutical Submits Hong Kong IPO Application
Bailey Tianheng (688506.SH) has submitted an application for the listing of H shares to the Stock Exchange of Hong Kong.
Bailitianheng (688506.SH) announced that the company is applying for a public offering of overseas listed stocks (H shares) and ...
Biokin Pharmaceutical Enrolls First Patient in Breast Cancer Drug Trial
No Data